SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 [Yahoo! Finance]
SCYNEXIS, Inc. (SCYX)
Last scynexis, inc. earnings: 11/12 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.scynexis.com/investor-relations
Company Research
Source: Yahoo! Finance
Scynexis Results from IV Phase 1 SAD/MAD Trial Expected in 2026 JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been dosed in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial evaluating the intravenous formulation (IV) of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026. “Following the FDA's recent decision to grant SCY-247 both Qualified Infections Disease Product and Fast Track designations, we are pleased to announce the dosing of the first cohort of participants in our Phase 1 SAD/MAD trial of IV SCY-247,” said David Angulo, M.D., President and Chie
Show less
Read more
Impact Snapshot
Event Time:
SCYX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCYX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCYX alerts
High impacting SCYNEXIS, Inc. news events
Weekly update
A roundup of the hottest topics
SCYX
News
- Scynexis: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
- SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247GlobeNewswire
- SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)GlobeNewswire
SCYX
Earnings
- 11/5/25 - Beat
SCYX
Sec Filings
- 3/4/26 - Form 10-K
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- SCYX's page on the SEC website